NCT05940272 Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
| NCT ID | NCT05940272 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Lymphoma, B-Cell |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2023-07-03 |
| Primary Completion | 2028-07-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 48 participants in total. It began in 2023-07-03 with a primary completion date of 2028-07-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
Eligibility Criteria
Inclusion Criteria: Providers * Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma) Patients * Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis) * Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma * Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT) * Self-identify as Black and/or White * Per medical record, 18 years of age or older * Per self-report, fluent in English\*\* * Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study: 1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused) 2. What is your preferred language for healthcare? (must respond English) Exclusion Criteria: Providers * Per self-report, planning to leave the cancer center in the next 12 months Patients * Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11 * Per research staff judgment and/or self-report, too ill or weak to complete study procedures * Per medical record or self-report, receiving hospice care at the time of enrollment
Contact & Investigator
Kelly McConnell, PhD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT05940272 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoma, B-Cell. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05940272 currently recruiting?
Yes, NCT05940272 is actively recruiting participants. Contact the research team at McConneK@mskcc.org for enrollment information.
Where is the NCT05940272 trial being conducted?
This trial is being conducted at New York, United States, New York, United States.
Who is sponsoring the NCT05940272 clinical trial?
NCT05940272 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Kelly McConnell, PhD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 48 participants.